Company Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States.
Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine.
Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022.
The company was incorporated in 2008 and is headquartered in Seattle, Washington. On December 19, 2023, Impel Pharmaceuticals Inc, along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.
| Country | WA |
| Founded | 2008 |
| IPO Date | Apr 23, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 160 |
Contact Details
Address: 201 Elliott Ave. W, Suite 260 Seattle, Washington 98119 | |
| Phone | 206-568-1466 |
Stock Details
| Ticker Symbol | IMPLQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001445499 |
| Employer ID | 26-3058238 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John D. Hoekman Ph.D. | Co-Founder and Chief Technology and Development Officer |
| Sarah Wille | Vice President of Human Resources |
| Scott Youmans | Senior Vice President of Technical Operations |
| Brandon Smith | Chief Restructuring Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2024 | 15-12G | Securities registration termination |
| Mar 12, 2024 | 8-K | Current Report |
| Feb 15, 2024 | EFFECT | Notice of Effectiveness |
| Feb 14, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 14, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 14, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 14, 2024 | POS AM | Post-Effective amendments for registration statement |
| Feb 14, 2024 | 8-K | Current Report |
| Jan 2, 2024 | 8-K | Current Report |
| Dec 27, 2023 | 25-NSE | Filing |